Nanotrap® Lyme Antigen Test
Until now, one of the only ways to detect Lyme disease was via blood tests. The Nanotrap® Lyme Antigen Test changes this. Thanks to nanotechnology, an active Lyme infection can be detected with the highest sensitivity and accuracy in every stage of the disease. Since the Nanotrap® Lyme Antigen Test was developed and optimized to detect Lyme disease in North American patients, additional development efforts are required to identify biomarkers that are better suited to detect Lyme disease in European infections. As such, the launch timeline for a European-specific Nanotrap® Lyme Antigen Test will be extended while the patient samples from Europe are evaluated to identify an appropriate biomarker.
Read more on the validation of the Nanotrap® LA test
How does the Nanotrap® test compare to the current diagnostics?
Most of the time, serological research is used to detect Lyme disease. This indirect way of testing doesn’t measure the disease itself, but measures the reaction of the body by looking at the present antibodies.
After an infection, it may take weeks or months before the antibodies can be measured. This means that when a patient is tested in an early phase of the disease, the result is false positive, because the level of antibodies isn’t high enough.
Another disadvantage is that the level of antibodies might remain high, even when a patient was successfully treated. This may cause a false positive result after a tick bite.
In short, to diagnose someone with Lyme disease on the basis of the symptoms and antibody tests is difficult and acquires extensive knowledge about the medical background of the patient and preferably multiple test over time.
The Nanotrap® Lyme Antigen Test
Thanks to the Nanotrap LA test, it is now possible to detect an active infection in every phase of the disease. The Nanotrap LA test measures the antigen of the Borrelia bacteria in human urine. This antigen is only present in urine when an active infection is going on. After successful treatment, this antigen will disappear from the urine.
Nanotechnology: how does it work?
The Nanotrap® Lyme Antigen Test uses nanotechnology. Small spheres with a ‘chemical anchor’ is added to the urine. This ‘anchor’ binds to the Borrelia proteins. This is how the present proteins in the urine are caught. Next, the nano-spheres are extracted from the urine, and the present protein is measured. By many doctors, this method is believed to be the future of Lyme diagnostics.
About Ceres, the producer
Ceres Nanosciences focuses on the development of research and diagnostic products with the help of the unique Nanotrap® technology. This technology offers strong methods to capture and process biomarkers for a wide range of diagnostic applications and the treatment of samples. The Nanotrap® technology was invented by the George Mason University, and was developed with the financial aid of the National Institutes of Health (NIH). With the help of the NIH, the Defense Advanced Research Projects Agency (DARPA), the Bill and Melinda Gates Foundation, and het Commonwealth of Virginia, Ceres focuses on the integration of this technology in a series innovative diagnostic products.
Ceres Nanosciences has asked Innatoss to execute the Nanotrap® Lyme Antigen Test for European patients. In this way, Europeans who suspect they have Lyme disease can also profit from the unique advantages this technology offers.